Shionogi aims to double flu-drug market with FDA-approved treatment

Japan's Shionogi & Co Ltd aims to double the global market for flu treatment with its drug Xofluza, the first flu drug approved by the U.S. Food and Drug Administration agency in nearly 20 years, its chief executive said. The drugmaker on Monday raised its full-year operating profit outlook to 124.5 billion yen , underpinned by an early approval for the new drug, beating the average market estimates of 121.08 billion yen, according to Refinitiv.

from Biotech News